NO20054710L - Immunmodulerende heterosykliske forbindelser - Google Patents

Immunmodulerende heterosykliske forbindelser

Info

Publication number
NO20054710L
NO20054710L NO20054710A NO20054710A NO20054710L NO 20054710 L NO20054710 L NO 20054710L NO 20054710 A NO20054710 A NO 20054710A NO 20054710 A NO20054710 A NO 20054710A NO 20054710 L NO20054710 L NO 20054710L
Authority
NO
Norway
Prior art keywords
heterocyclic compounds
immunomodulating
immunomodulating heterocyclic
solvate
hydrate
Prior art date
Application number
NO20054710A
Other languages
English (en)
Other versions
NO20054710D0 (no
NO332136B1 (no
Inventor
Ian Richard Mathews
Original Assignee
Avidex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0305876A external-priority patent/GB0305876D0/en
Priority claimed from GB0319429A external-priority patent/GB0319429D0/en
Application filed by Avidex Ltd filed Critical Avidex Ltd
Publication of NO20054710D0 publication Critical patent/NO20054710D0/no
Publication of NO20054710L publication Critical patent/NO20054710L/no
Publication of NO332136B1 publication Critical patent/NO332136B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Forbindelser med formel (I) er inhibitorer for CD80 og anvendbare i immunomodulasjonsterapi: hvor Ri og R3 uavhengig av hverandre er H, F, Cl, Br, -NO2, -CN, C1-C6 alkyl eventuelt substituert med F eller Cl, eller C1-C6 alkoksy eventuelt substituert med F; R4 er en karboksylsyregruppe (-COOH) eller en ester derav, eller -C(=O)NR6R7, -NR7C(=O)R6, -NR7C(=O)OR6, -NHC(=O)NR7R6 eller -NHC(=S)NR7R6 hvor Re er H, eller et radikal med formel -(Alk)m-Q hvor m is 0 or 1, Alk er et eventuelt substituert, toverdig, rettkjedet eller forgrenet C1-C12 alkylen-, C2-C12 alkenylen-, C2-C12 alkynylenradikal eller et toverdig C3-C12 karbosyklisk radikal, hvor alle radikalene kan inneholde en eller flere -O-, -S- eller -N(R8)-linkere hvor R8 er H eller d-C4 alkyl, C3-C4 alkenyl, C3-C4 alkynyl eller C3-C6 sykloalkyl, og Q er H, -NRgRiohvor R9 og Rio uavhengig av hverandre er H, C1-C4 alkyl, C3-C4 alkenyl, C3-C4 alkynyl, C3-C6 sykloalkyl, en estergruppe, en eventuelt substituert karbosyklisk eller heterosyklisk gruppe, eller R9 og Rio danner en ring sammen med nitrogenet som de er
NO20054710A 2003-03-14 2005-10-13 Immunomodulerende heterosyklisk forbindelse, anvendelse derav for fremstilling av et medikament, og farmasoytisk eller veterinaermedisinsk preparat omfattende forbindelsen NO332136B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0305876A GB0305876D0 (en) 2003-03-14 2003-03-14 Immuno inhibitory heterocyclic compounds
GB0319429A GB0319429D0 (en) 2003-08-19 2003-08-19 Immuno Inhibitory Heterocyclic compounds
PCT/GB2004/001008 WO2004081011A1 (en) 2003-03-14 2004-03-10 Immunomodulating heterocyclic compounds

Publications (3)

Publication Number Publication Date
NO20054710D0 NO20054710D0 (no) 2005-10-13
NO20054710L true NO20054710L (no) 2005-12-13
NO332136B1 NO332136B1 (no) 2012-07-02

Family

ID=32992598

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054710A NO332136B1 (no) 2003-03-14 2005-10-13 Immunomodulerende heterosyklisk forbindelse, anvendelse derav for fremstilling av et medikament, og farmasoytisk eller veterinaermedisinsk preparat omfattende forbindelsen

Country Status (19)

Country Link
US (3) US7276505B2 (no)
EP (2) EP1603917B1 (no)
JP (1) JP4892338B2 (no)
KR (1) KR101133959B1 (no)
AT (1) ATE489388T1 (no)
BR (1) BRPI0408365B8 (no)
CA (1) CA2519063C (no)
DE (1) DE602004030225D1 (no)
DK (1) DK1603917T3 (no)
EA (2) EA009680B1 (no)
EC (1) ECSP056104A (no)
IL (1) IL170389A (no)
MX (1) MXPA05009667A (no)
NO (1) NO332136B1 (no)
NZ (1) NZ541973A (no)
PL (2) PL1603917T3 (no)
PT (1) PT1603917E (no)
SI (1) SI1603917T1 (no)
WO (1) WO2004081011A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1603917E (pt) * 2003-03-14 2011-02-04 Medigene Ag Compostos heterocíclicos imunomoduladores
GB0325644D0 (en) * 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
GB0411770D0 (en) * 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
DE602004017231D1 (de) * 2004-08-09 2008-11-27 Medigene Ltd Immunmodulierende oxopyrazolocinnoline als cd80-inhibitoren
CA2618888A1 (en) * 2005-08-10 2007-02-15 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
GB0603522D0 (en) * 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition
JP2009530274A (ja) 2006-03-15 2009-08-27 ワイス ヒスタミン−3アンタゴニストとしてのn−置換−アザシクリルアミン化合物
EP2027086B1 (en) 2006-05-19 2011-11-16 Wyeth LLC N-benzoyl-pyrrolidin-3-ylamines as histamine-3 antagonists
US20100093867A1 (en) * 2006-07-05 2010-04-15 Ryoichi Matsuda Method Of Treating Genetic Disease Caused By Nonsense Mutation
PE20081152A1 (es) * 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
AR067549A1 (es) 2007-07-16 2009-10-14 Wyeth Corp Compuesto de oxazol,tiazol e imidazol, composicion farmaceutica que lo comprende , proceso para la preparacion del compuesto , uso del compuesto y metodos para la inhibicion del receptor h3 y para el tratamiento de un trastorno cognitivo relacionado con o afectado por el receptor de histamina -3 (h3
EP2020404A1 (en) * 2007-08-01 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Cyanomethyl substituted N-Acyl Tryptamines
WO2009043784A1 (en) 2007-10-04 2009-04-09 F. Hoffmann-La Roche Ag Cyclopropyl aryl amide derivatives and uses thereof
GB201021104D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
EP2676666A1 (en) 2012-06-20 2013-12-25 Eidgenössische Technische Hochschule Zürich (ETH) Compounds for use in diagnosis or therapy of vulnerable atherosclerotic plaques
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
CA2960277A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds
EP3558992A4 (en) 2016-12-15 2020-12-02 ONO Pharmaceutical Co., Ltd. TREK CHANNEL ACTIVATOR (K + CHANNELS ASSOCIATED WITH TWIK)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB629412A (en) 1946-12-24 1949-09-20 Geigy Ag J R Manufacture of metallisable monoazo dyestuffs of the pyrazolone series
US3576637A (en) 1967-04-20 1971-04-27 Konishiroku Photo Ind Lith-type of emulsion containing pyrozolone
JPS61161285A (ja) * 1984-12-28 1986-07-21 ルセル−ユクラフ ピラゾロ〔4,3−c〕シンノリン−3−オンの誘導体、それらの塩類、これらの製造法、薬剤としての使用、これらを含有する組成物及び中間体生成物
US4591589A (en) * 1985-01-16 1986-05-27 Roussel Uclaf 2-aryl pyrazolo[4,3-c]cinnolin-3-ones
DE3626221A1 (de) 1986-08-02 1988-02-04 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial zur herstellung farbiger aufsichtsbilder
US4906644A (en) 1986-11-20 1990-03-06 Mitsubishi Kasei Corporation Lipid-peroxide formation inhibiting composition and novel compounds useful therefor
DE3903993A1 (de) 1989-02-10 1990-08-16 Basf Ag Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
ID16283A (id) 1996-03-20 1997-09-18 Astra Pharma Prod Senyawa yang berguna dibidang farmasi
GB9713707D0 (en) 1997-06-27 1997-09-03 Merck Sharp & Dohme Therapeutic agents
SE0102404D0 (sv) * 2001-07-04 2001-07-04 Active Biotech Ab Novel immunomodulating compounds
WO2003004485A1 (fr) 2001-07-05 2003-01-16 Takeda Chemical Industries, Ltd. Composes heterocycles a 5 chainons condenses avec un benzo, leur procede de preparation et leur utilisation
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7081456B2 (en) 2002-11-22 2006-07-25 Active Biotech Ab Immunomodulatory compounds
EP1572689B1 (en) 2002-12-16 2009-03-11 Active Biotech AB Tetracyclic immunomodulatory compounds
PT1603917E (pt) 2003-03-14 2011-02-04 Medigene Ag Compostos heterocíclicos imunomoduladores
GB0325644D0 (en) 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
GB0411770D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
DE602004017231D1 (de) 2004-08-09 2008-11-27 Medigene Ltd Immunmodulierende oxopyrazolocinnoline als cd80-inhibitoren
US20060221590A1 (en) * 2005-03-31 2006-10-05 Edoardo Campini System and method for Advanced Mezzanine Card connection
GB0603522D0 (en) 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition

Also Published As

Publication number Publication date
CA2519063C (en) 2011-05-10
EP2284172A1 (en) 2011-02-16
MXPA05009667A (es) 2006-01-27
HK1090921A1 (zh) 2007-01-05
DK1603917T3 (da) 2011-02-28
IL170389A (en) 2013-08-29
CA2519063A1 (en) 2004-09-23
BRPI0408365B1 (pt) 2018-11-21
EP1603917A1 (en) 2005-12-14
NZ541973A (en) 2009-06-26
JP4892338B2 (ja) 2012-03-07
ATE489388T1 (de) 2010-12-15
AU2004220310A1 (en) 2004-09-23
KR101133959B1 (ko) 2012-04-09
US7276505B2 (en) 2007-10-02
BRPI0408365A (pt) 2006-03-21
WO2004081011A1 (en) 2004-09-23
ECSP056104A (es) 2006-03-01
KR20050121681A (ko) 2005-12-27
US20080045527A1 (en) 2008-02-21
US20090312334A1 (en) 2009-12-17
PT1603917E (pt) 2011-02-04
EA200501370A1 (ru) 2006-08-25
EA014080B1 (ru) 2010-08-30
US7598247B2 (en) 2009-10-06
PL1603917T3 (pl) 2011-12-30
SI1603917T1 (sl) 2011-04-29
PL383655A1 (pl) 2008-04-14
DE602004030225D1 (de) 2011-01-05
EA200702435A1 (ru) 2008-06-30
US8309552B2 (en) 2012-11-13
NO20054710D0 (no) 2005-10-13
EA009680B1 (ru) 2008-02-28
US20070021428A1 (en) 2007-01-25
NO332136B1 (no) 2012-07-02
JP2006520372A (ja) 2006-09-07
EP1603917B1 (en) 2010-11-24
BRPI0408365B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
DK1603917T3 (da) Immunmodulerende heterocycliske forbindelser
CY1107168T1 (el) Παραγωγα φαινυλοαλκανοϊκου οξεος και φαινυλοξυαλκανοϊκου οξεος ως ενεργοποιηται hppar
NL300927I9 (nl) Tivozanib of een zout, solvaat of hydraat ervan, in het bijzonder het hydrochloride-monohydraat
GB2398781B (en) Kinase inhibitors
IL165264A0 (en) Protein kinase inhibitors
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
PT1585739E (pt) Arilciclopropilacetamidas substitu?das como activadores da glucocinase
NO20061157L (no) 4-pyramidonderivater og deres anvendelse som peptidylpeptidmeinbibitorer
DE60319080D1 (de) Phenyloxyalkansäure-derivate als hppar aktivatore
EA200801381A1 (ru) Производные пиримидина
NO20054669L (no) Substituerte kinobenzoxazinanaloger
WO2006047528A3 (en) Pyrazolobenzamides and derivatives as factor xa inhibitors
MXPA05011276A (es) Derivado heterociclico de cinco miembros.
GB0215392D0 (en) Chemical compounds
DE602004031878D1 (de) Immunhemmende pyrazolon-verbindungen
TW200518748A (en) Chemical compounds
WO2004103305A3 (en) Spiropyrazole compound
DOP2002000354A (es) Compuestos farmaceuticamente activos.